Skip to main content
⏳GERIATRIC / PRECISION GEROMEDICINE

Aging & Precision Geromedicine

Treating aging itself — from managing age-related decline to senolytics, epigenetic reprogramming, and healthspan extension

Universal — aging underlies most chronic disease; ~1 billion people are over 60, rising to ~2 billion by 2050.
PRECLINICAL
60/ 100
TO BROAD CURE

MILESTONEBlocking cyclin D1–CDK6 suppresses inflammatory senescence genes (Nature Aging).

LATESTNature Communications reported LMNA-mediated CK2α/STING regulation reduces inflammaging via STING turnover.

Promising approaches remain at the lab / animal stage · Not medical advice.

CURRENT STATUS

Aging is being reframed as a modifiable driver of disease rather than an untouchable given. Senolytics that clear worn-out senescent cells are in early human trials; partial epigenetic reprogramming rejuvenates tissues in animal models; and geroprotectors such as rapamycin and metformin are being tested for healthspan. Single-cell aging atlases and epigenetic aging clocks enable precision, cell-type-specific interventions and let trials measure biological — not chronological — age. The central unsolved challenge is regulatory: aging is not yet a recognized indication, and validated functional endpoints (frailty, gait, immune age) are only now maturing. The honest clinical posture is to deploy proven healthspan levers today while treating unproven longevity products with real skepticism.

KEY BREAKTHROUGHS

Senolytics (dasatinib + quercetin, navitoclax) — clearing senescent cells to ease fibrotic and age-related disease in early human trials

Partial epigenetic reprogramming — transient Yamanaka factors rejuvenate retinal and other tissues in animal models (Altos, Retro, academic labs)

Aging clocks (epigenetic / proteomic) now quantify biological age, enabling trials to measure rejuvenation directly

Geroprotectors (rapamycin, metformin/TAME) being tested to compress age-related disease and extend healthspan

AI-COMPRESSED PIPELINE

AI TOOLS ACCELERATING CURES

Aging Clock / Biomarker AISingle-cell Aging AtlasSenescent-cell Target DiscoveryReprogramming Factor Optimization

KEY ORGANIZATIONS

Altos LabsUnity BiotechnologyCalicoRetro BiosciencesAcademic longevity centers

KEY CLINICAL TRIALS

TAME — Targeting Aging with Metformin

View

American Federation for Aging Research / academic

A landmark trial designed to test whether metformin can delay the onset of multiple age-related diseases at once — and, just as importantly, to establish aging itself as a treatable indication regulators will recognize.

👥 ~3,000 older adults (design/funding stage)📍 US — multicenter (planned)

Senolytic Therapy (Dasatinib + Quercetin) for Age-Related Disease

View

Academic consortia (Mayo Clinic and others)

Human trials testing whether intermittent senolytic dosing can clear senescent cells and improve outcomes in conditions like pulmonary fibrosis, frailty, and diabetic kidney disease — proof-of-concept for treating a hallmark of aging.

👥 Multiple Phase 1/2 studies📍 US — academic centers

TIMELINE ESTIMATE

Senolytics for specific age-related diseases: 3–6 years. Aging-biomarker-guided prevention: 5–10 years. Safe partial reprogramming in humans: 10–20 years.

EXPLORE FULL CURE PROTOCOL